Mitsubishi UFJ Asset Management
NKTR icon

Mitsubishi UFJ Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,971
Closed -$539K – 1028
2019
Q3 		$539K Sell
1,971
-703
-26% -$258K 0.01% 726
2019
Q2 		$1.43M Buy
2,674
+353
+15% +$177K 0.02% 546
2019
Q1 		$1.17M Buy
2,321
+156
+7% +$92.4K 0.02% 530
2018
Q4 		$1.02M Sell
2,165
-86
-4% -$51.9K 0.03% 521
2018
Q3 		$2.06M Buy
2,251
+815
+57% +$696K 0.04% 404
2018
Q2 		$1.05M Buy
1,436
+1,238
+625% +$1.43M 0.02% 568
2018
Q1 		$315K Buy
+198
New +$255K 0.01% 729

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Mitsubishi UFJ Asset Management's NKTR Position: Q4 2019 in Review

Mitsubishi UFJ Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 1,971 shares — an estimated $539K sold.

Mitsubishi UFJ Asset Management first reported a position in NKTR in Q1 2018 and held it in 7 quarters. The position peaked at $2.06M in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Mitsubishi UFJ Asset Management reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 1,971 Nektar Therapeutics shares in Q4 2019, an estimated $539K.
  • Mitsubishi UFJ Asset Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 7 quarters.
  • Mitsubishi UFJ Asset Management's Nektar Therapeutics position peaked at $2.06M in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2019, filed 5 Feb 2020.